OR WAIT null SECS
Move helps biosimulation consulting support for clients in China, as well as support China's expansion of its fast-track drug approval process.
Certara®, a global biosimulation technology-enabled drug development company, announced the launch of Certara Strategic Consulting China in Shanghai. The new company will be led by President and CEO Christine Yuying Gao, MD, PhD, former vice president of consulting services at Quantitative Solutions, a global pharmacometrics consulting company. Quantitative Solutions merged with Certara’s Pharsight Consulting Services in July 2015 to form Certara Strategic Consulting.
Read the full release.